Skip to main content

Advertisement

Log in

Role of Additional Organ Resection in Adrenocortical Carcinoma: Analysis of 167 Patients from the U.S. Adrenocortical Carcinoma Database

  • Endocrine Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Adrenocortical carcinoma (ACC) is a rare and aggressive cancer. This report describes factors and outcomes associated with resection of extra-adrenal organs en bloc during index adrenalectomy.

Methods

Patients who underwent ACC resection for non-metastatic disease from 1993 to 2014 at 13 participating institutions of the US-ACC Group were included in the study. Factors associated with en bloc resection were assessed by uni- and multivariate analysis. The primary end point was overall survival.

Results

In this study, 167 patients were included and categorized as adrenalectomy with en bloc resection (AdEBR) if they had extra-adrenal organs removed or adrenalectomy (Ad) if they did not. The demographics were similar between the AdEBR (n = 68, 40.7%) and Ad groups, including age, gender, race, American Society of Anesthesiology (ASA) class, and body mass index (BMI). The AdEBR group had larger tumors (13 vs. 10 cm), more open operations (97.1 vs. 63.6%), and more lymph node dissections (LNDs) (36.8 vs. 12.1%). The most common organs removed were kidney (55.9%), liver (27.9%), and spleen (23.5%). Multiple organs were removed in 38.2% (n = 26) of the patients. Margin-negative resections were similar between the two groups. In the multivariate Cox regression adjusted for T and N stages, LND, margin, size, and hormone hypersecretion, en bloc resection was not associated with improved survival (hazard ratio [HR], 1.42; p = 0.323).

Conclusion

The study findings validated current practice by showing that en bloc resection should occur at index adrenalectomy for ACC when a T4 lesion is suspected pre- or intraoperatively, or when it is necessary to avoid tumor rupture. However, in this study, when a negative margin resection was otherwise achieved, removal of extra-adrenal organs en bloc was not associated with additional survival benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States. Cancer. 2008;113:3130–6. https://doi.org/10.1002/cncr.23886.

    Article  PubMed  Google Scholar 

  2. Kebebew E, Reiff E, Duh Q-Y, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: Have we made progress? World J Surg. 2006;30:872–8. https://doi.org/10.1007/s00268-005-0329-x.

    Article  PubMed  Google Scholar 

  3. Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg. 2001;25:891–7. https://doi.org/10.1007/s00268-001-0047-y.

    Article  PubMed  CAS  Google Scholar 

  4. LaFemina J, Brennan MF. Adrenocortical carcinoma: past, present, and future. J Surg Oncol. 2012;106:586–94. https://doi.org/10.1002/jso.23112.

    Article  PubMed  CAS  Google Scholar 

  5. Gaujoux S, Weinandt M, Bonnet S, Reslinger V, Bertherat J, Dousset B. Surgical treatment of adrenal carcinoma. J Visc Surg. 2017;154:335–43. https://doi.org/10.1016/j.jviscsurg.2017.06.010.

    Article  PubMed  CAS  Google Scholar 

  6. Sidhu S, Sywak M, Robinson B, Delbridge L. Adrenocortical cancer: recent clinical and molecular advances. Curr Opinion Oncol. 2003;16:13–8.

    Article  Google Scholar 

  7. Ayala-Ramirez M, Jasim S, Feng L, et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013;169:891–9. https://doi.org/10.1530/eje-13-0519.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999;6:719–26.

    Article  PubMed  CAS  Google Scholar 

  9. Kendrick ML, Lloyd R, Erickson L, et al. Adrenocortical carcinoma: Surgical progress of status quo? Arch Surg. 2001;136:543–9.

    Article  PubMed  CAS  Google Scholar 

  10. Mihai R. Diagnosis, treatment, and outcome of adrenocortical cancer. Br J Surg. 2015;102:291–306. https://doi.org/10.1002/bjs.9743.

    Article  PubMed  CAS  Google Scholar 

  11. Margonis GA, Kim Y, Prescott JD, et al. Adrenocortical carcinoma: impact of surgical margin status on long-term outcomes. Ann Surg Oncol. 2015;23:134–41. https://doi.org/10.1245/s10434-015-4803-x.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Chagpar R, Siperstein AE, Berber E. Adrenocortical cancer update. Surg Clin North Am. 2014;94:669–87. https://doi.org/10.1016/j.suc.2014.02.009.

    Article  PubMed  Google Scholar 

  13. Hermsen I, Kerkhofs T, Butter den G, et al. Surgery in adrenocortical carcinoma: importance of national cooperation and centralized surgery. Surgery. 2012;152:50–6. https://doi.org/10.1016/j.surg.2012.02.005.

    Article  PubMed  Google Scholar 

  14. Livhits M, Li N, Yeh MW, Harari A. Surgery is associated with improved survival for adrenocortical cancer, even in metastatic disease. Surgery. 2014;156:1531–41. https://doi.org/10.1016/j.surg.2014.08.047.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Fassnacht M, Johanssen S, Fenske W, et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab. 2010;95:4925–32. https://doi.org/10.1210/jc.2010-0803.

    Article  PubMed  CAS  Google Scholar 

  16. Lombardi CP, Raffaelli M, Boniardi M, et al. Adrenocortical carcinoma: effect of hospital volume on patient outcome. Langenbecks Arch Surg. 2011;397:201–7. https://doi.org/10.1007/s00423-011-0866-8.

    Article  PubMed  Google Scholar 

  17. Gaujoux S, Brennan MF. Clinical review recommendation for standardized surgical management of primary adrenocortical carcinoma. Surgery. 2012;152:123–32. https://doi.org/10.1016/j.surg.2011.09.030.

    Article  PubMed  Google Scholar 

  18. Grubbs EG, Callender GG, Xing Y, et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol. 2009;17:263–70. https://doi.org/10.1245/s10434-009-0716-x.

    Article  PubMed  Google Scholar 

  19. Ip JCY, Pang TCY, Glover AR, et al. Improving outcomes in adrenocortical cancer: an Australian perspective. Ann Surg Oncol. 2014;22:2309–16. https://doi.org/10.1245/s10434-014-4133-4.

    Article  PubMed  Google Scholar 

  20. Miller BS, Gauger PG, Hammer GD, Doherty GM. Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery. 2012;152:1150–7. https://doi.org/10.1016/j.surg.2012.08.024.

    Article  PubMed  Google Scholar 

  21. Cooper AB, Habra MA, Grubbs EG, et al. Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma? Surg Endosc. 2013;27:4026–32. https://doi.org/10.1007/s00464-013-3034-0.

    Article  PubMed  Google Scholar 

  22. Huynh KT, Lee DY, BJ L, Flaherty DC, Lee J, Goldfarb M. Impact of laparoscopic adrenalectomy on overall survival in patients with nonmetastatic adrenocortical carcinoma. J Am Coll Surg. 2016;223:485–92. https://doi.org/10.1016/j.jamcollsurg.2016.05.015.

    Article  PubMed  Google Scholar 

  23. Gerry JM, Tran TB, Postlewait LM, et al. Lymphadenectomy for adrenocortical carcinoma: Is there a therapeutic benefit? Ann Surg Oncol. 2016;23:708–13. https://doi.org/10.1245/s10434-016-5536-1.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Reibetanz J, Jurowich C, Erdogan I, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg. 2012;255:363–9. https://doi.org/10.1097/sla.0b013e3182367ac3.

    Article  PubMed  Google Scholar 

  25. Miller BS, Doherty GM. Regional lymphadenectomy for adrenocortical carcinoma. Ann Surg. 2013;257:e13–4. https://doi.org/10.1097/sla.0b013e3182891ee5.

    Article  PubMed  Google Scholar 

  26. Bittner JG, Gershuni VM, Matthews BD, Moley JF, Brunt LM. Risk factors affecting operative approach, conversion, and morbidity for adrenalectomy: a single-institution series of 402 patients. Surg Endosc. 2013;27:2342–50. https://doi.org/10.1007/s00464-013-2789-7.

    Article  PubMed  Google Scholar 

  27. Icard P, Louvel A, Chapuis Y. Survival rates and prognostic factors in adrenocortical carcinoma. World J Surg. 2018;16:753–8.

    Article  Google Scholar 

  28. Dindo D, Demartines N, Clavien P-A. Classification of surgical complications. Ann Surg. 2004;240:205–13. https://doi.org/10.1097/01.sla.0000133083.54934.ae.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Grubbs EG, Callender GG, Xing Y, et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol. 2009;17:263–70. https://doi.org/10.1245/s10434-009-0716-x.

    Article  PubMed  Google Scholar 

  30. Amini N, Margonis GA, Kim Y, et al. Curative resection of adrenocortical carcinoma: rates and patterns of postoperative recurrence. Ann Surg Oncol. 2015;23:126–33. https://doi.org/10.1245/s10434-015-4810-y.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Chapgar R, Siperstain AE, Berber E. Adrenocortical cancer update. Surg Clin North Am. 2014;94:669–87. https://doi.org/10.1016/j.suc.2014.02.009.

    Article  Google Scholar 

  32. Bellantone R, Ferrante A, Boscherini M, et al. Role of reoperation in recurrence of adrenal cortical carcinoma: tesults from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery. 1997;122:1212–8.

    Article  PubMed  CAS  Google Scholar 

  33. Laan DV, Thiels CA, Glasgow A, et al. Adrenocortical carcinoma with inferior vena cava tumor thrombus. Surgery. 2017;161:240–8. https://doi.org/10.1016/j.surg.2016.07.040.

    Article  PubMed  Google Scholar 

  34. Zhang HM, Perrier ND, Grubbs EG, et al. CT features and quantification of the characteristics of adrenocortical carcinomas on unenhanced and contrast-enhanced studies. Clin Radiol. 2012;67:38–46. https://doi.org/10.1016/j.crad.2011.03.023.

    Article  PubMed  CAS  Google Scholar 

  35. Chiche L, Dousset B, Kieffer E, Chapuis Y. Adrenocortical carcinoma extending into the inferior vena cava: presentation of a 15-patient series and review of the literature. Surgery. 2006;139:15–27. https://doi.org/10.1016/j.surg.2005.05.014.

    Article  PubMed  Google Scholar 

  36. Hedican SP, Marshall FF. Adrenocortical carcinoma with intracaval extension. J Urol. 1997;158:2056–61.

    Article  PubMed  CAS  Google Scholar 

  37. Keskin S, Tas F, Vatansever S. Adrenocortical carcinoma: clinicopathological features, prognostic factors and outcome. Urol Int. 2013;90:435–8. https://doi.org/10.1159/000345489.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Carmen C. Solórzano MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marincola Smith, P., Kiernan, C.M., Tran, T.B. et al. Role of Additional Organ Resection in Adrenocortical Carcinoma: Analysis of 167 Patients from the U.S. Adrenocortical Carcinoma Database. Ann Surg Oncol 25, 2308–2315 (2018). https://doi.org/10.1245/s10434-018-6546-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-018-6546-y

Keywords

Navigation